Please login to the form below
EU
This page shows the latest EU news and features for those working in and with pharma, biotech and healthcare.
Moderna’s Omicron booster receives MHRA approval
Moderna has completed regulatory submissions for mRNA-1273.214 in the EU, Australia and Canada and anticipates further authorisations over the next few weeks.
Latest news
-
Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
The drug is currently approved in more than 70 markets around the world, including the US, EU Japan and China, to treat adults with non-metastatic castration-resistant prostate cancer (nmCRPC)
-
Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
The drug was approved in the US in November 2019 and is also approved in the EU, the UAE, Oman and Britain.
-
Amgen acquires ChemoCentryx in $3.7bn cash deal
The treatment is also approved in major markets outside the US, including the EU and Japan.
-
GSK to supply 85 million doses of pandemic influenza vaccine to EU
Through this agreement for 85 million doses, we can help the EU and European countries, as well as other countries and regions, be better prepared for future pandemics.”. ... officially declared by the World Health Organization (WHO) or the EU.
-
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
patients in the EU.”.
More from news
Approximately 143 fully matching, plus 2,311 partially matching documents found.
Latest Intelligence
-
Environment: where does the pharmaceutical industry stand?
In Japan this is already the case, but EU and US regulators are yet to approve the move to digital instructions.
-
Pharma’s authentic proof of purpose influences decisions among HCPs and payers
Our research was conducted over several weeks in 2020 with over 2, 000 healthcare professionals across a wide range of therapy areas in the US and EU Big Five, as well
-
Piloting a route to the biosimilars opportunities in Europe
Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy. ... By the end of 2020, it was estimated that biosimilars had saved the EU up to $44bn in healthcare costs.
-
EU cross-border healthcare
accessible information is established, to navigate the cross- border healthcare framework for all stakeholders (ie, a dedicated EU website). ... The development of Commission guidelines that set harmonised review and approval timelines that will expedite
-
From if to how: when imagination and regulation work together
For example, there are 30 million people in the EU who live with a rare disease, for whom the perceived lack of prioritisation is stark.
More from intelligence
Approximately 9 fully matching, plus 202 partially matching documents found.
Latest appointments
-
David Hunt launches independent agency The Considered
awards, including Cannes Lions Healthcare Agency of the Year, PMEA EU Healthcare Agency of the Year and Creative Floor Most Awarded Agency.
-
Ashfield Engage appoints Serap Becker as head of patient solutions in DACH region
Benjamin Rapp, regional president EU South at Ashfield Engage.
-
EFPIA confirms first and second vice-presidents
I look forward to working with the EFPIA Board and the wider community to achieve the shared goal of building a future EU health and innovation union.”. ... Realising that goal means EFPIA and its membership working with the EU and Member States to
-
Hanover Health appoints Aleksandra Lugović as an associate director
Lugović joins from GOPA Com. Brussels, where she ran global campaigns for the European Commission across the EU, US, Africa and Asia. ... Prior to that, she headed the regional representation of South Serbia to the EU for a period of six years.
-
EFPIA appoints Hubertus von Baumbach as president
He added: “Over the coming months, my colleagues and I look forward to engaging with the EU Institutions and across Member States to discuss how we can work together to ensure ... that the EU remains an innovation leader and to build a healthier future
More from appointments
Approximately 2 fully matching, plus 67 partially matching documents found.
Latest from PMHub
-
Infographic: Therapy Watch Lupus
Therapy Watch Lupus patient data is collected from a panel of 600 physicians across the main 5 EU markets, China, Japan, and the US.
-
Traversing the Medtech Regulatory Landscape in the Interest of Patients
Bassil Akra, CEO of AKRA TEAM GmbH, takes a deep dive into the new approval process for medical devices in the EU and shares how his company is supporting Medical Device ... and In Vitro Diagnostic companies to get safe, qualitative, and well-performing
-
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. ... of its proposal on the update of EU pharmaceutical legislation by the end of 2022.
-
Learning to invest in doctors’ education
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more
-
Engaging doctors around the globe
Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies are now exploring and exploiting a
More from PMHub
Approximately 4 fully matching, plus 147 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Environment: where does the pharmaceutical industry stand?
- ONS data reveals significant decrease in COVID-19 antibodies
- Novartis reports death of two patients treated with Zolgensma
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Are we the masters or servants of omnichannel engagement?
- JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign
- AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients
- Gilead Sciences announce positive results for Trodelvy in breast cancer patients
- UK government to launch national mission to tackle dementia
- WHO publishes first position paper on optimising brain health
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- Sanofi halts recruitment for trials assessing MS treatment
- Environment: where does the pharmaceutical industry stand?
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Avastin wins EU approval for advanced renal cancer
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
